Stock PAR PARADIGM BIOPHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Paradigm Biopharmaceuticals Limited

Equities

PAR

AU000000PAR5

Market Closed - Australian S.E.
Other stock markets
 02:10:52 2024-06-03 am EDT 		5-day change 1st Jan Change
0.25 AUD 0.00% Intraday chart for Paradigm Biopharmaceuticals Limited -1.96% -41.18%
Apr. 19 Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program MT
Feb. 28 Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up
AQ
Paradigm Biopharmaceuticals : Quarterly Update and Appendix 4C - quarterly
PU
Paradigm Biopharmaceuticals : Application for quotation of securities - PAR
PU
Paradigm Biopharmaceuticals : Quarterly Update and Appendix 4C - quarterly
PU
Paradigm Biopharmaceuticals : Half Yearly Report and Accounts
PU
Paradigm Biopharmaceuticals : Notification regarding unquoted securities - PAR
PU
Paradigm Biopharmaceuticals : Quarterly Update and Appendix 4C - quarterly
PU
Paradigm Biopharmaceuticals : AGM Presentation
PU
Paradigm Biopharmaceuticals : PAR REPORTS POSTIVE TOPLINE RESULTS IN HEART FAILURE MODEL
PU
Paradigm Biopharmaceuticals : Application for quotation of securities - PAR
PU
Paradigm Presentation to Bell Potter Healthcare Conference
PU
Paradigm Biopharmaceuticals : Cleansing Notice and Appendix 3B
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PAR Stock
  4. News Paradigm Biopharmaceuticals Limited
  5. Press Releases